David Goldenberg takes over CEO position following resignation of President & CEO Robert DeLuccia, the company announces June 2. DeLuccia will remain at the company in an advisory position during the management transition. Goldenberg, founder of the Morris Plains, N.J.-based biopharm company, served as Immunomedics CEO in the past. The company also names Immunomedics Europe General Manager Philippe Barzin VP-global marketing and business development at U.S. headquarters
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth